References
- Siegel R, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014 Jan;64(1):9–29.
- Borazanci E, Von Hoff DD. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2014 May 31:1–9.
- National Comprehensive Cancer Network. NCCN Guidelines Version 2.2014. Pancreatic adenocarcinoma. Available online at www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Last accessed July 30, 2014.
- Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31; 369(18):1691–703.
- Fan KY, et al. Baseline hemoglobin-A1C impacts clinical outcomes in patients with pancreatic cancer. J Natl Compr Canc Netw. 2014 Jan;12(1):50–7.
- Von Hoff DD, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010 Nov 20;28(33):4877–83.
- Tsimberidou AM, et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: Validation and landmark analyses. Clin Cancer Res. 2014 Jul 1. Epub ahead of print.
- Von Hoff D, et al. NAPOLI-1: randomized phase 3 study of MM-398 (Nal-Iri), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy. Presented at: the ESMO 16th World Congress on Gastrointestinal Cancer; June 25-28, 2014; Barcelona, Spain. Abstract O-0003.
- Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–23.
- Hamid O, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11;369(2):134–44.